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OBJECTIVES This study sought to assess the potential utility of impedance cardiography (ICG) in
predicting clinical deterioration in ambulatory patients with heart failure (HF).
BACKGROUND Impedance cardiography uses changes in thoracic electrical impedance to estimate
hemodynamic variables, but its ability to predict clinical events has not been evaluated.
METHODS We prospectively evaluated 212 stable patients with HF and a recent episode of clinical
decompensation who underwent serial clinical evaluation and blinded ICG testing every 2
weeks for 26 weeks and were followed up for the occurrence of death or worsening HF
requiring hospitalization or emergent care.
RESULTS During the study, 59 patients experienced 104 episodes of decompensated HF (16 deaths, 78
hospitalizations, and 10 emergency visits). Multivariate analysis identified 6 clinical and ICG
variables that independently predicted an event within 14 days of assessment. These included three
clinical variables (visual analog score, New York Heart Association functional class, and systolic
blood pressure) and three ICG parameters (velocity index, thoracic fluid content index, and left
ventricular ejection time). The three ICG parameters combined into a composite score was a
powerful predictor of an event during the next 14 days (p  0.0002). Visits with a high-risk
composite score had 2.5 times greater likelihood and those with a low-risk score had a 70% lower
likelihood of a near-term event compared with visits at intermediate risk.
CONCLUSIONS These results suggest that when performed at regular intervals in stable patients with HF with
a recent episode of clinical decompensation, ICG can identify patients at increased near-term
risk of recurrent decompensation. (J Am Coll Cardiol 2006;47:2245–52) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.071American College of Cardiology Foundation
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Ghe course of patients with chronic heart failure (HF) is
arked by periodic episodes of clinical decompensation that
ot only impair the quality of life and may be fatal but also
onsume substantial health care resources, primarily because
f the costs of hospitalization (1). Heart failure manage-
ent programs have been developed to reduce the frequency
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vents may afford physicians the opportunity to intervene
ggressively and potentially minimize the need for hospital-
zation or the risk of a serious adverse outcome.
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Utility of Impedance Cardiography June 6, 2006:2245–52Some investigators have hypothesized that the measure-
ent of hemodynamic variables might identify patients
ikely to deteriorate clinically during follow-up (3–5). How-
ver, prior studies have shown the prognostic value of
emodynamic measurements only over periods too long to
llow for immediate intervention to prevent imminent
ccurrence of a serious clinical event (5). However, periodic
eassessment might be useful in identifying high-risk pa-
ients if cardiocirculatory variables could be estimated accu-
ately and noninvasively.
Noninvasive impedance cardiography (ICG) uses changes in
horacic electrical impedance to measure thoracic fluid content,
hanges in the duration of cardiac ejection, and the velocity of
lood flow within the aorta (6,7). Impedance cardiography has
een used to estimate cardiac output and cardiac filling
ressure in patients with and without HF (6–11), but little is
nown about its ability to predict episodes of clinical
ecompensation.
ETHODS
tudy patients. Patients were included if they had chronic
F attributable to an ischemic or nonischemic cause (re-
ardless of ejection fraction); had New York Heart Associ-
tion (NYHA) functional class II, III, or IV symptoms; and
ere receiving appropriate medications for heart failure. All
atients had a hospitalization, emergency department visit,
r unscheduled clinic visit for worsening HF within three
onths, but had no meaningful change in symptoms or
edications for heart failure within seven days.
Patients were excluded if they had any of the following:
eight 47 or 91 inches; weight 66 or 342 lbs; HF
aused by myocarditis, cor pulmonale, congenital heart
isease, constrictive pericarditis, or hypertrophic or restric-
ive cardiomyopathy; hemodynamically significant aortic
egurgitation; acute coronary syndrome or coronary revas-
ularization within 2 months; history of resuscitated sudden
eath or symptomatic or sustained ventricular fibrillation or
entricular tachycardia (unless within 24 h of a myocardial
nfarction or treated with a implantable cardioverter-
efibrillator that had not fired within 2 months); second-
egree Mobitz type II or third-degree heart block (unless
reated with a pacemaker); left ventricular assist device or an
ctivated minute ventilation pacemaker; any planned use of
ntravenous medications for HF (diuretics, vasodilators, or
Abbreviations and Acronyms
HF  heart failure
ICG  impedance cardiography
LVET  left ventricular ejection time
NYHA  New York Heart Association
SI  stroke index
TFC  thoracic fluid content
TFCI  thoracic fluid content index
VI  velocity indexositive inotropic agents); serum creatinine 5 mg/dl; any iiver function test 3 times the upper limit of normal or
ialysis within 2 weeks; pulmonary disease that contributed
o the limitation of exercise or required long-term cortico-
teroids; hypersensitivity to sensor gel or adhesive; skin
esions that prohibited sensor placement; or a disorder other
han heart failure that might compromise survival within 6
onths. The study was approved by the institutional review
oard at each participating institution. All patients provided
ritten, informed consent.
tudy design. After an initial assessment, patients were
cheduled to undergo a clinical assessment and an ICG test as
n outpatient every 2 weeks for 26 weeks. The clinical as-
essment included vital signs and weight, patient self-
ssessment of HF using a visual analog score, and NYHA
unctional class. The ICG measurements (Table 1) were
erformed in a blinded manner using a BioZ ICG Monitor
CardioDynamics, San Diego, California) and stored in the
onitor’s electronic memory for subsequent analysis.
hroughout the study, patients were managed according to
he judgment of their usual physicians, who had no knowl-
dge of the ICG test results.
All patients were followed up throughout the study for
he occurrence of a HF event, which was prospectively
efined in the original protocol as death from any cause or
ospitalization or emergency department visit for worsening
F that required intensification of treatment. A committee
f three cardiologists adjudicated all hospitalizations and
mergency visits without knowledge of their clinical or ICG
ariables to determine whether events were related to
orsening HF.
tatistical analyses. The prespecified primary hypothesis
f the study was that changes in ICG variables combined
nto a composite score would predict the occurrence of a
ajor clinical event. The variables were to be identified in
n initial cohort of approximately 200 patients and then
alidated in a second cohort of similar size. This report
escribes the results in the first patient cohort; the second
ohort has not yet been studied.
To test the primary study hypothesis, patients were
ategorized regarding whether they had or had not experi-
nced one or more HF events during the study. Visits were
ategorized into those immediately preceding and those not
mmediately preceding a HF event. Differences in variables
easured at visits preceding and not preceding an event
ere tested for significance by t test. A 14-day window was
sed retrospectively to define “immediate” because the study
isits were scheduled every 2 weeks. General estimation
quation modeling was used to predict the occurrence of a
F event. Dependence in repeated data within a subject
as modeled with an autoregressive covariance structure
nd a logistic link function to address the binary nature of
he end point. A backward stepwise approach (which
ncluded all baseline, clinical, change in clinical variables
rom the prior visit, and ICG variables) was used to identify
ndependent predictor variables, which were then validated
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June 6, 2006:2245–52 Utility of Impedance Cardiographyith a forward stepwise procedure and ranked according to
hi-square value.
To assess the ability of multiple ICG variables to simul-
aneously predict a HF event, the independently associated
CG variables were combined into a single composite score
sing weights derived from the multivariate model. The
egression equation generated a value for each patient visit
hat was translated into the log of odds for a HF event and
hen converted to a numeric score between 0 and 10 with a
igher score denoting higher risk.
Event rates for each group were calculated by dividing the
umber of visits that preceded an event by the total number
f visits. Event rates were converted to relative risks (with
5% confidence intervals) by dividing the reference event
ate by the comparator event rate. Differences in event rates
nd relative risks were assessed by two-tailed Fisher exact
ests.
ESULTS
total of 212 patients were enrolled at 21 sites in the U.S.
he patients were 21 to 91 years of age (mean 59 years);
4% were men and 35% were black. The cause of HF was
oronary artery disease in 46%; the mean ejection fraction
as 0.27  0.14 (range 0.10 to 0.76), and 17% had an
jection fraction0.40. Functional status was class II in 32%,
lass III in 66%, and class IV in 3%. Treatment included
Table 1. Impedance Cardiography Variables
ICG Variable U
Blood flow
SV ml
SI ml/m2
CO l/min
CI l/min/m2
Resistance
Systemic vascular resistance dyne  s 
Systemic vascular resistance index dyne  s 
Stroke systemic resistance index dyne  cm
Contractility
VI /1,000/s
Acceleration index /100/s2
PEP ms
LVET ms
STR —
Systolic time ratio index /s
Cardiac work
Left stroke work index g  m/m2
Left cardiac work index kg  m/m2
Fluid status
Thoracic fluid content /kOhm
Thoracic fluid content index /kOhm/m2
BSA body surface area; CI cardiac index; CO cardiac
Hg); ECG  electrocardiography; HR  heart rate; ICG 
MAP  mean arterial pressure; PCWP  pulmonary cap
pre-ejection period; RR interval  60/heart rate; SI  stroke
volume of electrically participating tissue; VI  velocity indeiuretics (96%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (84%), beta-blockers (72%),
igoxin (62%), and aldosterone antagonists (41%).
The 212 patients completed 2,316 study visits (mean
0.9  3.8 visits per patient). Twenty patients did not
omplete the study (15 because of a patient request, 4
ecause of a physician request, and 1 because of a serious
dverse event unrelated to ICG measurement), but all
vailable data in these 20 patients are included in the
nalysis.
During the study, there were 104 HF events in 59
atients (27.8%), which included 16 deaths, 78 hospitaliza-
ions for worsening HF (in 50 patients), and 10 emergency
epartment visits for worsening HF (in 10 patients). Of the
04 events, 80 events (8 deaths, 64 hospitalizations, and 8
mergency visits) occurred within 14 days of a study visit,
nd of the 2,316 visits, 77 visits preceded an event within 14
ays, equating to a 14-day heart failure event rate of 3.3%.
or these visits, the mean time from the visit to the event
as 5.9  4.5 days.
There were no significant differences in baseline demo-
raphic, clinical, or ICG variables in patients with or
ithout a HF event during the study. However, when the
nalysis was confined to visits within 14 days of an event,
everal variables had predictive value (Table 2). The patient
isual analog scores and systolic blood pressures were lower
nd the heart rates and NYHA functional class were higher
Measurement/Calculation
VI  LVET  VEPT (Z-MARC
algorithm)
SV/BSA
SV  HR
CO/BSA
5 [(MAP  CVP)/CO]  80
5  m2 [(MAP  CVP)/CI]  80
m2 [(MAP  CVP)/SI]  80
1,000  first time derivativemax/
baseline impedance
100  second time derivativemax/
baseline impedance
ECG Q-wave to aortic valve opening
Aortic valve opening to closing
PEP/LVET
STR/RR interval
(MAP  PCWP)  SI  0.0136
(MAP  PCWP)  CI  0.0144
1,000  1/baseline impedance
1,000  1/baseline impedance/BSA
t; CVP central venous pressure (estimated value of 10 mm
dance cardiography; LVET  left ventricular ejection time;
wedge pressure (estimated value of 10 mm Hg); PEP 
; STR  systolic time ratio; SV  stroke volume; VEPT 
ARC  impedance modulating aortic compliance.nits
cm
cm
5 
outpu
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Utility of Impedance Cardiography June 6, 2006:2245–52receding an event. In addition, ICG assessment indicated
ore severe cardiocirculatory abnormalities (lower stroke
olume, cardiac output, stroke work indices, velocity
ndex [VI], and left ventricular ejection time [LVET],
nd higher vascular resistance, systolic time ratio index,
nd thoracic fluid content [TFC] index [TFCI]) at visits
mmediately preceding an event compared with those not
receding an event.
Multivariate regression analysis identified three clinical
ariables (visual analog score, NYHA functional class, and
ystolic blood pressure) and three ICG variables (TFCI, VI,
nd LVET) that were independently associated with the
ccurrence of a heart failure event within the next 14 days
Table 3). These three ICG variables were then combined
nto a single ICG composite score ranging from 0 to 10,
ith a higher score indicating higher risk for a heart failure
vent. The logit for the ICG composite score was calculated
ased on the following equation: () () TFCI ()
I  () LVET, where , , , and  are constants
eflecting the unique weighting of each variable. The ICG
omposite score was significantly higher in visits immediately
Table 2. Clinical and ICG Variables Measured
Immediately Preceding a Heart Failure Event
Variable
Visits
a H
Eve
(
Clinical
New York Heart Association
functional class
Heart rate (beats/min) 7
Patient visual analog score 7
Systolic blood pressure (mm Hg) 12
Weight (change in lbs from
previous visit)
Diastolic blood pressure (mm Hg) 7
Impedance cardiography
SI (ml/m2) 3
SV (ml) 6
Left stroke work index (g  m/m2) 3
LVET (ms)
VI (/1,000/s) 3
STR index (/s) 0
Thoracic fluid content (/kOhm) 3
Thoracic fluid content index
(/kOhm/m2)
1
Stroke systemic resistance index
(dyne  cm5  m2)
Left cardiac work index (kg  m/m2)
CO (l/min)
Acceleration index (/100/s2) 6
CI (l/min/m2)
Systemic vascular resistance
(dyne  s  cm5)
1,
Pre-ejection period (ms)
Systemic vascular resistance index
(dyne  s  cm5  m2)
3,
Systolic time ratio (no units) 0
Abbreviations as in Table 1.receding an event when compared with visits not immediately Vreceding an event (6.1  2.0 vs. 4.4  1.9, p  0.0001).
Visits closer to an event were not disproportionately weighted
n the ICG score because the ICG scores in the 51 visits within
days of an event were not different than the scores in the 26
isits within 8 to 14 days of an event [6.1 1.6 vs. 6.0 2.2].)
hen the multivariate analysis was repeated using the com-
osite ICG score along with the three clinical predictors, the
omposite score was the most powerful predictor of an event
ithin the next 14 days (Table 3).
Table 4 shows the HF event rate and relative risks for
ach ICG score. Because most study visits did not precede
n event, there was a nonlinear distribution of risk across
core values, and thus the ICG scores were grouped into
ow-, intermediate-, and high-risk categories (correspond-
ng to scores of 0 to 3, 4 to 6, and 7 to 10, respectively).
isits with a high-risk ICG score had an 8.4% event rate
uring the next 14 days; high scores were present in only
6.5% of visits, but they predicted 41.6% of the events. In
ontrast, visits with a low-risk ICG score had only a 1.0%
vent rate within 14 days; low scores were present in 38.6%
f visits but were followed by only 11.7% of the events.
isits Immediately Preceding and Not
Preceding
Failure
14 Days
,239)
Visits Preceding a
Heart Failure
Event <14 Days
(n  77) p Value
0.6 3.0  0.5 0.0001
13.5 80.0  17.1 0.0001
19.8 60.2  21.6 0.0001
22.5 116.0  20.7 0.0023
6.0 0.3  7.4 0.4702
13.7 72.1  12.9 0.5025
9.7 27.4  10.5 0.0001
21.8 54.6  22.9 0.0001
12.7 29.2  13.2 0.0001
38 248  39 0.0002
15.2 28.7  13.9 0.0003
0.31 0.80  0.33 0.0017
9.2 37.4  11.8 0.0020
5.2 18.7  6.5 0.0029
135 300  202 0.0055
0.85 2.4  0.88 0.0094
1.36 4.2  1.5 0.0096
30.2 59.1  26.7 0.0230
0.6 2.1  0.7 0.0243
880 1,870  989 0.0440
33 135  27 0.0545
1,604 3,658  1,876 0.0739
0.19 0.58  0.17 0.3235at V
Not
eart
nt <
n  2
2.6 
1.0 
3.0 
3.9 
0.8 
3.1 
3.0 
6.2 
5.7 
265 
5.0 
.68 
3.1 
6.4 
234 
2.6 
4.6 
7.0 
2.3 
664 
141 
266 
.56 isits with a high-risk ICG score had a 2.5 times higher
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June 6, 2006:2245–52 Utility of Impedance Cardiographyikelihood and those with a low-risk score had a 70% lower
ikelihood of a near-term HF event when compared with
isits at intermediate risk (Table 4). Visits with a high-risk
CG score were 8.3 (95% CI 5.7 to 11.5) times more likely
o be followed by an event within 14 days than those with
low-risk score. When NYHA functional class was added
o the ICG composite score model, it did not improve the
bility to discern high- or low-risk visits.
Table 3. Multivariate Analysis of Association o
a Heart Failure Event Within 14 Days
Variable Chi-Squ
Considering ICG variables
individually
Patient visual analog score 11.76
Thoracic fluid content index
(/kOhm/m2)
8.57
New York Heart Association
functional class
8.37
VI (/1,000/s) 7.32
Systolic blood pressure (mm Hg) 5.56
LVET (ms) 3.85
Considering ICG variables together as
composite score
ICG score 13.83
Patient visual analog score 10.98
New York Heart Association
functional class
9.22
Systolic blood pressure (mm Hg) 4.94
CI  confidence interval; other abbreviations as in Table 1.
able 4. Frequency of Occurrence and Value of ICG Scores in P
Displayed by
ICG Score
Visits
(%)
Heart Failure
Events (%)
0 9 (0.4) 0 (0.0)
1 43 (1.9) 0 (0.0)
2 295 (12.7) 4 (5.2)
3 546 (23.6) 5 (6.5)
4 434 (18.7) 11 (14.3)
5 242 (10.4) 6 (7.8)
6 364 (15.7) 19 (24.7)
7 205 (8.9) 14 (18.2)
8 127 (5.5) 12 (15.6)
9 29 (1.3) 3 (3.9)
10 22 (0.9) 3 (3.9)
Grouped Into
Risk Group
ICG Score
Range Visits (%)
Heart Fail
Events (%
ow risk 0–3 893 (38.6) 9 (11.7
ntermediate risk 4–6 1,040 (44.9) 36 (46.8
igh risk 7–10 383 (16.5) 32 (41.6Model p value  0.0001; †p  0.001 for differences between intermediate vs. low risk an
CI  confidence interval; RR  relative risk; other abbreviations as in Table 1.Two ICG parameters, stroke index (SI) and TFC, were
sed to create four unique cardiocirculatory quadrants in a
anner similar to that originally proposed by Forrester et al.
3) to identify risk subsets after an acute myocardial infarc-
ion (Fig. 1). Visits with an SI 35 ml/m2 and a TFC 35
kOhm were followed by a risk of only 0.9% of a heart
ailure event as compared with a risk of 6.5% for visits with
n SI 35 ml/m2 and a TFC 35 /kOhm. Visits in the
inical and ICG Variables With Occurrence of
p Value Odds Ratio (95% CI)
0.0006 1.22 (1.10–1.35) per 10-U decrease
0.0034 1.51 (1.24–1.83) per 5-U/kOhm/m2
increase
0.0038 2.32 (1.43–3.77) per 1-class increase
0.0068 1.36 (1.08–1.72) per 10/1,000/s
decrease
0.0184 1.15 (1.02–1.29) per 10-mm Hg
decrease
0.0496 1.33 (1.09–1.63) per 25-ms decrease
0.0002 1.45 (1.27–1.66) per 1-U decrease
0.0009 1.21 (1.10–1.35) per 10-U decrease
0.0024 2.38 (1.46–3.86) per 1-class increase
0.0263 1.13 (1.01–1.28) per 10-mm Hg
decrease
ting Occurrence of a Heart Failure Event Within 14 Days
idual Scores*
Event Rate (%)
(95% CI)
RR vs. Intermediate Risk
(95% CI)
0.0 (0.0–33.6) 0.0 (0.0–10.11)
0.0 (0.0–8.2) 0.0 (0.0–2.47)
1.4 (0.4–3.4) 0.41 (0.11–1.03)
0.9 (0.3–2.1) 0.28 (0.09–0.64)
2.5 (1.3–4.5) 0.76 (0.38–1.35)
2.5 (0.9–5.3) 0.75 (0.28–1.60)
5.2 (3.2–8.0) 1.57 (0.95–2.42)
6.8 (3.8–11.2) 2.05 (1.14–3.37)
9.5 (5.0–15.9) 2.84 (1.50–4.79)
10.3 (2.2–27.4) 3.11 (0.66–8.23)
13.6 (2.9–34.9) 4.10 (0.87–10.50)
Categories†
Event Rate (%)
(95% CI)
RR vs.
Intermediate Risk
(95% CI)
RR vs.
Low Risk
(95% CI)
1.0 (0.5–1.9) 0.30 (0.14–0.57) —
3.5 (2.4–4.8) 1.04 (0.73–1.43) 3.43 (2.42–4.72)
8.4 (5.8–11.6) 2.51 (1.74–3.49) 8.29 (5.74–11.50)f Cl
areredic
Indiv
Risk
ure
)
)
)
)d intermediate vs. high risk; p  0.0001 for difference between high vs. low risk.
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Utility of Impedance Cardiography June 6, 2006:2245–52ighest-risk quadrant had seven times (95% confidence
nterval 4.7 to 9.9) the risk of an event as did visits in the
ow-risk quadrant.
ISCUSSION
he flow of blood within the thorax can produce striking
ut transient changes in electrical impedance, which may be
etected by ICG (6,7). By assessing the change in imped-
nce of an alternating current applied across the chest, this
echnique can measure the baseline impedance as well as the
agnitude and duration of the change in impedance during
ystole (Fig. 2). These measurements lead directly to the
alculation of TFC, VI, and LVET, which can be used
lone or in combination to estimate hemodynamic param-
ters (6–11). However, ICG may complement rather than
eplicate the information provided by right heart catheter-
zation. Although estimates of cardiac output and stroke
olume by ICG seem to be related to estimates of these
ariables by thermodilution (9,10), ICG may not reliably
stimate right and left ventricular filling pressures (10,12)
ecause cardiac filling pressures are influenced by changes in
ardiac contractility and loading conditions, whereas TFC
aries with radioisotopic estimates of plasma volume and
hus may reflect the quantity of intravascular and extravas-
ular fluid within the chest (13–16). Furthermore, the
nvasive nature of cardiac catheterization restricts its repet-
tive use, whereas ICG can be used to perform serial
oninvasive assessments, thus allowing it to potentially
etect the emergence of potentially adverse hemodynamic
hanges during periods of apparent clinical stability.
Despite these theoretical advantages, little is known
bout the ability of ICG to predict changes in cardiac
unction or clinical status or the occurrence of clinical events
n HF. In one retrospective chart review of 13 patients (17),
relationship was observed between changes in impedance
arameters and changes in ejection fraction over six months.
n a second retrospective chart review of 64 patients (18),
hanges in impedance variables were related to changes in
igure 1. All patient visits were placed into one of four hemodynamic
uadrants according to values of stroke index and thoracic fluid content.
or each quadrant, the number of visits fulfilling the criteria for the
uadrant, the number of heart failure events within 14 days of these visits,
nd the event rates (and associated 95% confidence intervals) are shown.YHA functional class, corridor walk distance, visual ana-
c
(og score, and quality of life over 6 months. In a third study
f 98 men seen in an emergency department (19), a
ombination of brain natriuretic peptide and ICG variables
as reported to identify patients at risk of death and
ospitalization, but the independent contribution of ICG
easurements was not assessed (20). Until the present
eport, no study had prospectively evaluated the ability of
CG to predict clinical events.
In the current prospective study, we found that ICG can
dentify patient visits likely to be followed in the near-term
ut not necessarily in the long-term by a clinical event. Over
period of six months, three variables directly assessed by
CG (TFCI, VI, LVET) were each powerful independent
redictors of the occurrence of death or a worsening HF
vent during the 14 days after testing. Furthermore, when
ombined into a single composite score, these three vari-
bles provided powerful short-term prognostic information
hat was incremental to that available from a physician’s
linical evaluation. However, neither clinical nor ICG vari-
bles measured at the start of the study identified patients who
igure 2. Thoracic fluid content describes inverse value of the level of
aseline impedance (Z) within the thorax, from which the Z waveform
riginates. Velocity index describes the maximum deflection of the first
erivative of the Z waveform, shown as the Z/t waveform (C point).
re-ejection period (PEP) is measured from ventricular depolarization (Q
oint) to aortic valve opening (B point). Left ventricular ejection time
LVET) is measured from aortic valve opening (B point) to aortic valve
losure (X point). Pulmonic valve closure (Y point) and mitral valve closure
O point) can also be identified. ECG  electrocardiogram.
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June 6, 2006:2245–52 Utility of Impedance Cardiographyeteriorated, suggesting that the predictive value of both
linical and ICG measurements may wane over time. This
bservation underscores the need for periodic reassessment and
lose follow-up for the optimal management of patients.
Impedance cardiography can generate a wide range of
ardiocirculatory variables (Table 1), including those that
re directly measured from the impedance waveforms, those
hat are derived from two or more ICG measurements, and
hose that are calculated from a combination of clinical and
CG assessments. Some investigators have suggested that
easurements derived from combinations of ICG variables
ight increase the utility of the device (21,22), but this
ypothesis has not been evaluated. It is therefore notewor-
hy that in the current study the three ICG variables that
rovided strong and independent prognostic information
TFCI, VI, and LVET) were not derived measurements,
ut were determined directly from the raw impedance
aveforms. Simultaneous consideration of more than one of
hese independent variables seemed to improve their pre-
ictive value not when they were combined to generate a
erived variable, but when their individual contributions
ere retained in a composite score or were used to formulate
orrester-like risk quadrants (3,4,22). These combined
nalyses were prognostically more powerful and discrimi-
ating than any variable considered alone.
Do ICG variables provide prognostic information that is
ncremental to that already available to the practicing
hysician? Clinicians assess the status of patients and gauge
he need for therapeutic adjustments by taking a history of
ecent symptoms and performing a physical examination to
ssess fluid retention. This evaluation leads to an overall
hysician-based assessment (e.g., NYHA functional class)
nd an overall patient-based assessment (e.g., visual analog
core), which are considered together with vital signs and
ody weight. The current study confirms the independent
ontribution made by each component of a physician’s
ypical clinical assessment (NYHA functional class, patient
isual analog score, and systolic blood pressure) (23). How-
ver, in this study, the prognostic information provided by
CG seemed to complement that provided by the clinical
ssessment.
The findings of the current study should be interpreted
autiously. First, although our findings are consistent with
ur original hypothesis, the hypothesis for this pilot trial was
ot specific and could have been confirmed by a number of
ossible outcomes, including the one observed. To address
his concern, the original protocol specified that the findings
n the first cohort had to be validated in a second cohort;
his validation has not yet occurred. Second, the risk models
hat we reported in the present study did not include the
CG data collected before 24 of the 104 (23%) events seen
n the study because their ICG tests were delayed beyond
ur 14-day window. Widening of the window to 16 or 18
ays so to include some of these excluded events would not
ave qualitatively altered our findings but would have
educed our estimates of the magnitude of incremental risk essociated with a high-risk score. Third, we did not have
omplete proximate data for clinical events for periods
onger than 14 days for patients enrolled in first and final 2
eeks of the study, thus our data sets were not sufficiently
omplete to evaluate the prognostic value of ICG beyond 14
ays. Fourth, although specific values for certain ICG
ariables were associated with a higher risk, this association
oes not consider the relative frequency of visits with low-
r high-risk scores. As in the case of other prognostic
ariables, the majority of patients with high-risk scores did
ot experience near-term events and the majority of events
ook place in patients with low- or intermediate-risk scores.
inally, although our findings suggest that the ICG test
dds information to certain clinical variables used alone, in
linical practice physicians assess patients using a combina-
ion of clinical variables—some objective and measured
e.g., body weight and systolic blood pressure), some sub-
ective and measured (e.g., NYHA functional class and
atient global assessment), and some subjective and unmea-
ured (e.g., the overall impression and prior experience with
he patient). The current study could not determine whether
CG adds value to a weighted composite of all clinical
nformation typically available to clinicians during their
outine management of patients.
As a result, our finding that specific clinical and ICG
ariables had predictive value should not be construed to
mply that such variables can be used to titrate therapeutic
gents or monitor their effectiveness. Although one study
uggested that knowledge of ICG parameters can alter a
hysician’s treatment plans (24), and others have suggested
hat ICG parameters improve when patients receive effec-
ive drugs for heart failure (25,26), it is not clear whether
CG-directed modifications improve clinical outcomes be-
ond that expected if physicians responded appropriately to
linical signals in the absence of ICG data. In the Evalua-
ion Study of Congestive Heart Failure and Pulmonary
rtery Catheterization Effectiveness (ESCAPE) (27), the
se of in-hospital invasive hemodynamic measurements to
itrate treatment failed to alter long-term outcomes, but
uch assessments were not repeated during the period of
ollow-up. A large-scale clinical trial is now being planned
o assess whether treatment guided by repeated assessment
f a combination of clinical and ICG data reduces the risk
f an adverse event when compared with clinical data alone.
In conclusion, our results suggest that when performed at
egular intervals in patients with heart failure with a recent
pisode of clinical decompensation, noninvasive assessment by
CG can identify patients at near-term risk of recurrent
ecompensation. The clinical importance of these findings is
urrently being tested in a large-scale trial.
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